Methods:
TriNetX global research network provided aggregate data for this
retrospective cohort study of AF patients on liraglutide that were
matched to AF patients not on liraglutide from January 1, 2016, through
November 13, 2021. Primary outcomes were all-cause mortality, ischemic
stroke, hemorrhagic stroke, acute heart failure episode, and acute
coronary syndrome episode.